Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.

Portage Biotech Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

DOVER, DEL., JULY 25, 2025 (GLOBE NEWSWIRE) -- PORTAGE BIOTECH INC. (PORTAGE OR THE COMPANY) (NASDAQ: PRTG), A CLINICAL-STAGE IMMUNO-ONCOLOGY COMPANY FORMED UNDER THE LAWS OF THE BRITISH VIRGIN ISLANDS, WITH A PORTFOLIO OF NOVEL MULTI-TARGETED THERAPIES FOR USE AS MONOTHERAPY AND IN COMBINATION, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE FISCAL YEAR ENDED MARCH 31, 2025.

PORTAGE BIOTECH REPORTS RESULTS FOR FISCAL YEAR ENDED MARCH 31, 2025

DOVER, DEL., JUNE 25, 2025 (GLOBE NEWSWIRE) -- PORTAGE BIOTECH INC. (PORTAGE OR THE COMPANY) (NASDAQ: PRTG), A CLINICAL-STAGE IMMUNO-ONCOLOGY COMPANY FORMED UNDER THE LAWS OF THE BRITISH VIRGIN ISLANDS (PORTAGE), ANNOUNCED TODAY THAT ON JUNE 24, 2025, THE COMPANY RECEIVED FORMAL NOTICE FROM THE NASDAQ STOCK MARKET LLC THAT THE COMPANY HAS EVIDENCED COMPLIANCE WITH ALL APPLICABLE REQUIREMENTS FOR CONTINUED LISTING ON THE NASDAQ CAPITAL MARKET.

PORTAGE BIOTECH REGAINS FULL COMPLIANCE WITH NASDAQ CONTINUED LISTING REQUIREMENTS

DOVER, DEL., JUNE 09, 2025 (GLOBE NEWSWIRE) -- PORTAGE BIOTECH INC. (NASDAQ: PRTG), A CLINICAL-STAGE IMMUNO-ONCOLOGY COMPANY FORMED UNDER THE LAWS OF THE BRITISH VIRGIN ISLANDS (PORTAGE) ANNOUNCE THAT ON JUNE 5, 2025 PORTAGE AND COMPEDICA HOLDINGS LIMITED, A COMPANY FORMED UNDER THE LAWS OF THE ISLE OF MAN (COMPEDICA) ENTERED A MUTUAL SUBSCRIPTION AGREEMENT (SUBSCRIPTION AGREEMENT).

PORTAGE BIOTECH AND COMPEDICA STOCK-FOR-STOCK EXCHANGE

DOVER, DEL., APRIL 28, 2025 (GLOBE NEWSWIRE) -- PORTAGE BIOTECH INC. (NASDAQ: PRTG), A CLINICAL-STAGE IMMUNO-ONCOLOGY COMPANY TODAY REPORTS CONFIRMATORY PRECLINICAL EFFICACY DATA FOR PORT-7 (TT-4), A SELECTIVE ADENOSINE A2B RECEPTOR INHIBITOR.

PORTAGE BIOTECH REPORTS CONFIRMATORY PRECLINICAL RESULTS IN MESOTHELIOMA SUPPORTING FIRST-IN-HUMAN TRIAL OF PORT-7

ENCOURAGING SAFETY PROFILE SUPPORTS PROGRESSION TOWARD FIRST DUAL-ADMINISTRATION OF SELECTIVE A2A AND A2B ANTAGONISTS IN PATIENTS ENCOURAGING SAFETY PROFILE SUPPORTS PROGRESSION TOWARD FIRST DUAL-ADMINISTRATION OF SELECTIVE A2A AND A2B ANTAGONISTS IN PATIENTS

PORTAGE BIOTECH RESUMES ENROLLMENT IN FINAL COHORT OF DOSE ESCALATION FOR PORT-6 IN ADPORT-601 TRIAL

DOVER, DEL., FEB. 12, 2025 (GLOBE NEWSWIRE) -- PORTAGE BIOTECH, INC. (PORTAGE OR THE COMPANY) (NASDAQ: PRTG), A CLINICAL-STAGE IMMUNO-ONCOLOGY COMPANY WITH A PORTFOLIO OF INNOVATIVE THERAPEUTICS, TODAY ANNOUNCED THAT ON FEBRUARY 11, 2025, IT RECEIVED NOTIFICATION FROM THE NASDAQ STOCK MARKET, LLC (NASDAQ) THAT NASDAQ HAS ACCEPTED PORTAGE'S COMPLIANCE PLAN AND HAS GRANTED THE COMPANY THE EXTENSION TO REGAIN COMPLIANCE WITH THE CONTINUED LISTING STANDARDS ON THE NASDAQ CAPITAL MARKET (THE CAPITAL MARKET) AS SET FORTH IN NASDAQ LISTING RULE 5550(B)(1) WHEREBY THE MINIMUM SHAREHOLDERS' EQUITY IS AT LEAST $2.5 MILLION OR MEET EITHER OF THE ALTERNATIVE CONTINUED LISTING STANDARDS FOR THE CAPITAL MARKET, RELATING TO MARKET VALUE OF LISTED SECURITIES OF AT LEAST $35 MILLION OR NET INCOME FROM CONTINUED OPERATIONS OF AT LEAST $500,000 IN THE MOST RECENTLY COMPLETED FISCAL YEAR OR IN TWO OF THE LAST THREE MOST RECENTLY COMPLETED FISCAL YEARS.

PORTAGE BIOTECH RECEIVES EXTENSION OF TIME TO ATTAIN COMPLIANCE WITH STOCK EXCHANGE CONTINUED LISTING REQUIREMENTS

DOVER, DEL., JAN. 30, 2025 (GLOBE NEWSWIRE) -- PORTAGE BIOTECH, INC. (PORTAGE OR THE COMPANY) (NASDAQ: PRTG), A CLINICAL-STAGE IMMUNO-ONCOLOGY COMPANY WITH A PORTFOLIO OF INNOVATIVE THERAPEUTICS, TODAY ANNOUNCED THAT IT HAS COMPLETED A PRIVATE PLACEMENT OF $2.15 MILLION FROM TWO PORTAGE DIRECTORS.

PORTAGE BIOTECH ANNOUNCES COMPLETION OF $2.15 MILLION PRIVATE FINANCING

WESTPORT, CONN., JAN. 06, 2025 (GLOBE NEWSWIRE) -- PORTAGE BIOTECH, INC. (PORTAGE OR THE COMPANY) (NASDAQ: PRTG), A CLINICAL-STAGE IMMUNO-ONCOLOGY COMPANY WITH A PORTFOLIO OF INNOVATIVE THERAPEUTICS, TODAY ANNOUNCED THE RE-LAUNCH OF ITS WHOLLY-OWNED SUBSIDIARY AS AN INDEPENDENTLY MANAGED COMPANY FOCUSED ON DEVELOPING BEST-IN-CLASS ADENOSINE RECEPTOR ANTAGONISTS.

PORTAGE BIOTECH ANNOUNCE RE-LAUNCH OF ADENOSINE SUBSIDIARY AS INDEPENDENTLY MANAGED COMPANY; APPOINTMENT OF PETER MOLLOY TO LEAD NEW COMPANY

NO IMPACT AT THIS TIME ON THE LISTING OF THE COMPANY'S ORDINARY SHARES ON NASDAQ COMPANY INTENDS TO SUBMIT TO NASDAQ A COMPLIANCE PLAN WESTPORT, CONN., DEC. 12, 2024 (GLOBE NEWSWIRE) -- PORTAGE BIOTECH INC. (PORTAGE OR THE COMPANY) (NASDAQ: PRTG), A CLINICAL-STAGE IMMUNO-ONCOLOGY COMPANY WITH A PORTFOLIO OF NOVEL MULTI-TARGETED THERAPIES FOR USE AS MONOTHERAPY AND IN COMBINATION, ANNOUNCED TODAY THAT IT RECEIVED WRITTEN NOTICE (THE NOTICE) FROM THE NASDAQ STOCK MARKET, LLC (NASDAQ) ON DECEMBER 10, 2024 INDICATING THAT THE COMPANY WAS NOT IN COMPLIANCE WITH THE MINIMUM SHAREHOLDERS' EQUITY REQUIREMENT FOR CONTINUED LISTING ON THE NASDAQ CAPITAL MARKET (THE CAPITAL MARKET) AS SET FORTH IN NASDAQ LISTING RULE 5550(B)(1) (THE SHAREHOLDERS' EQUITY REQUIREMENT), BECAUSE THE COMPANY'S SHAREHOLDERS' EQUITY OF $695,000 AS OF SEPTEMBER 30, 2024, AS REPORTED IN THE COMPANY'S REPORT ON FORM 6-K CONTAINING UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2024, FILED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION (THE SEC) ON NOVEMBER 26, 2024, WAS BELOW THE REQUIRED MINIMUM OF $2.5 MILLION, AND BECAUSE, AS OF THE DATE OF THE NOTICE (AND AS OF THE DATE OF THIS PRESS RELEASE), THE COMPANY DID NOT MEET EITHER OF THE ALTERNATIVE CONTINUED LISTING STANDARDS FOR THE CAPITAL MARKET, RELATING TO MARKET VALUE OF LISTED SECURITIES OF AT LEAST $35 MILLION OR NET INCOME FROM CONTINUING OPERATIONS OF AT LEAST $500,000 IN THE MOST RECENTLY COMPLETED FISCAL YEAR OR IN TWO OF THE LAST THREE MOST RECENTLY COMPLETED FISCAL YEARS.

PORTAGE BIOTECH ANNOUNCES RECEIPT OF NASDAQ NONCOMPLIANCE LETTER

WESTPORT, CONN., NOV. 26, 2024 (GLOBE NEWSWIRE) -- PORTAGE BIOTECH INC. (PORTAGE OR THE COMPANY) (NASDAQ: PRTG), A CLINICAL-STAGE IMMUNO-ONCOLOGY COMPANY WITH A PORTFOLIO OF NOVEL MULTI-TARGETED THERAPIES FOR USE AS MONOTHERAPY AND IN COMBINATION, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE FISCAL QUARTER ENDED SEPTEMBER 30, 2024.

Portage Biotech Inc.

PRTG

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Portage Biotech Inc.

PRTG.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

PRTG